Comparison between the efficacy of intravenous immunoglobulin and convalescent plasma in COVID-19
Phase 3
Recruiting
- Conditions
- COVID-19 disease.
- Registration Number
- IRCT20200413047056N1
- Lead Sponsor
- Birjand University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
RT-PCR Confirm the infection in the throat swab or sputum or lower respiratory tract samples.
Sign the Informed Consent Form on a voluntary basis.
Meet any of the following criteria for severe or critical ill conditions:Respiratory rate >=30/min; orRest SPO2<=90%; orPaO2/FiO2<=300mmHg; orRespiratory failure and needs mechanical ventilation; orMultiple organ failure and needs ICU monitoring
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ung involvement in X-ray and CT-scan, SPO2, LDH enzyme, viral load, acute phase protein, white blood cell count, ESR, length of hospital stay, duration of mechanical ventilation. Timepoint: from the start of the intervention for 12 days. Method of measurement: Blood and biochemical factors are measured using laboratory tests by an autoanalyzer. Pulmonary function indicators are measured by pulse oximetry and ABG.
- Secondary Outcome Measures
Name Time Method